Trial Profile
A Randomized Phase II Study of Chemoradiation and Pembrolizumab for Locally Advanced Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Apr 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Cisplatin
- Indications Cervical cancer
- Focus Adverse reactions; Pharmacodynamics
- 26 Apr 2021 Planned End Date changed from 1 Oct 2021 to 1 Dec 2021.
- 26 Apr 2021 Status changed from recruiting to active, no longer recruiting.
- 15 Nov 2020 Planned End Date changed from 1 May 2021 to 1 Oct 2021.